当前位置: X-MOL 学术Lung Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Lung Cancer ( IF 4.5 ) Pub Date : 2020-03-12 , DOI: 10.1016/j.lungcan.2020.03.008
Shira Sherman 1 , Ofer Rotem 1 , Tzippy Shochat 2 , Alona Zer 1 , Assaf Moore 1 , Elizabeth Dudnik 1
Affiliation  

OBJECTIVES Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS. MATERIALS AND METHODS Thirty-seven consecutive patients with advanced LCNEC were selected from the Davidoff Cancer Center database. These were divided into groups A1 (patients treated with ICPi, n-23) and A2 (patients not treated with ICPi, n-14). Additionally, group A1* was introduced (patients treated with ICPi as a monotherapy, n-21). Another cohort of advanced non-LCNEC lung cancer patients treated with nivolumab at five Israeli cancer centers was chosen as a comparator (group B, n-270). ORR, PFS with ICPi in group A1* were assessed (RECIST 1.1), OS with ICPi was compared between groups A1* and B. OS since advanced disease diagnosis (OSDx) was compared between groups A1 and A2. RESULTS In group A1*, ORR and median PFS with ICPi were 33 %, and 4.2 months (95 % CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in groups A1* and B, respectively, 52 % and 64 % of patients died in groups A1* and B, respectively. Median OS with ICPi comprised 11.8 months (95 % CI, 3.7-NR) and 6.9 months (95 % CI, 5.5-8.1) in groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95 % CI, 10.1-38.9) and 10.3 months (95 % CI, 2.6-NR), in groups A1 and A2, respectively (p-0.54). CONCLUSION In advanced LCNEC, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future research is needed to clarify the impact of ICPi on OS, and to correlate its benefit with tumor mutational landscape.

中文翻译:

免疫检查点抑制剂(ICPi)在肺大细胞神经内分泌肿瘤(LCNEC)中的功效。

目的关于LCNEC中ICPi的功效知之甚少。我们探讨了ICPi在LCNEC中的功效和安全性,并评估了其对OS的影响。材料与方法从Davidoff癌症中心数据库中选择了连续的37例晚期LCNEC患者。将其分为A1组(接受ICPi,n-23治疗的患者)和A2(未接受ICPi,n-14治疗的患者)。此外,引入了A1 *组(使用ICPi作为单一疗法治疗的患者,n-21)。选择在以色列的五个癌症中心接受尼古鲁单抗治疗的另一组晚期非LCNEC肺癌患者作为比较者(B组,n-270)。评估了A1 *组的ORR,PFS和ICPi(RECIST 1.1),在A1 *和B组之间比较了带有ICPi的OS。由于在A1和A2组之间比较了晚期疾病诊断(OSDx),因此比较了OS。结果在A1 *组中,ICPi的ORR和中位PFS分别为33%和4.2个月(95%CI,2.4-8.1)。自从ICPi开始以来,A1 *和B组的中位随访时间分别为6.2个月[IQR 2.2-12.1]和4.9个月[IQR 2.3-8.9],A1 *和B组分别有52%和64%的患者死亡, 分别。A1 *组和B组的ICPi中位OS分别为11.8个月(95%CI,3.7-NR)和6.9个月(95%CI,5.5-8.1)(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。分别为2个月(95%CI,2.4-8.1)。自从ICPi开始以来,A1 *和B组的中位随访时间分别为6.2个月[IQR 2.2-12.1]和4.9个月[IQR 2.3-8.9],A1 *和B组分别有52%和64%的患者死亡, 分别。A1 *组和B组的ICPi中位OS分别为11.8个月(95%CI,3.7-NR)和6.9个月(95%CI,5.5-8.1)(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。分别为2个月(95%CI,2.4-8.1)。自从ICPi开始以来,A1 *和B组的中位随访时间分别为6.2个月[IQR 2.2-12.1]和4.9个月[IQR 2.3-8.9],A1 *和B组分别有52%和64%的患者死亡, 分别。A1 *组和B组的ICPi中位OS分别为11.8个月(95%CI,3.7-NR)和6.9个月(95%CI,5.5-8.1)(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。A1 *和B组分别有9个月[IQR 2.3-8.9],A1 *和B组分别有52%和64%的患者死亡。A1 *组和B组的ICPi中位OS分别为11.8个月(95%CI,3.7-NR)和6.9个月(95%CI,5.5-8.1)(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。A1 *和B组分别有9个月[IQR 2.3-8.9],A1 *和B组分别有52%和64%的患者死亡。A1 *组和B组的ICPi中位OS分别为11.8个月(95%CI,3.7-NR)和6.9个月(95%CI,5.5-8.1)(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。分别为(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。分别为(p-0.23)。在A1和A2组中,OSDx的中位数分别为14.5个月(95%CI,10.1-38.9)和10.3个月(95%CI,2.6-NR)(p-0.54)。结论在晚期LCNEC中,ICPi结果与晚期NSCLC中观察到的结果相当。需要进一步的研究来阐明ICPi对OS的影响,并将其益处与肿瘤突变景观联系起来。
更新日期:2020-03-12
down
wechat
bug